Takashi Kawasuji

USPTO Granted Patents = 16 (Patent Applications = 24)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 225(Granted Patents)

Location History:

Toyonaka, JP (2018)
Osaka, JP (2009 - 2022)

Company Filing History:

16 out of 1,001

Shionogi Company Limited

patents

10 out of 40

Viiv Healthcare Company

where one patent can have more than one assignee

Years Active: 2009-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11267823 - Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity (2022-03-08),

2. 10927129 - N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity (2021-02-23),

3. 9975906 - Tricyclic heterocycle derivatives having HIV replication inhibitory effect (2018-05-22),

4. 9572813 - Antiviral agent (2017-02-21),

5. 9365587 - Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates (2016-06-14),

6. 9273065 - Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors (2016-03-01),

7. 9242986 - Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates (2016-01-26),

8. 9051337 - Substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1h-pyrido[1,2-a]pyrrolo[1',2′:3,4]imidazo[1,2-d]pyrazine-8-carboxamides (2015-06-09),

9. 8778943 - [object Object] (2014-07-15),

10. 8754214 - Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates (2014-06-17),

11. 8624023 - Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates (2014-01-07),

12. 8410103 - (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent (2013-04-02),

13. 8188271 - Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity (2012-05-29),

14. 8129385 - Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness (2012-03-06),

15. 7858788 - Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity (2010-12-28),

Title: Takashi Kawasuji: Pioneering Innovator in Technology

Introduction:

Takashi Kawasuji, a visionary inventor based in Osaka, Japan, has been at the forefront of technological innovation, inspiring a new generation of inventors to strive for excellence. With a remarkable portfolio of 16 patents to his name, Kawasuji's work has significantly impacted the field of technology.

Latest Patents:

Kawasuji's latest patents include groundbreaking inventions such as Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines with HIV integrase inhibitory activity and N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide with HIV integrase inhibitory activity. These patents demonstrate Kawasuji's dedication to addressing crucial healthcare challenges.

Career Highlights:

With a prolific career, Takashi Kawasuji has worked with esteemed companies such as Shionogi & Company Limited and Viiv Healthcare. His tenure at these companies has been marked by groundbreaking research and the development of innovative solutions in the field of healthcare technology.

Collaborations:

Throughout his career, Kawasuji has collaborated with talented individuals such as Yoshiyuki Taoda and Brian Alvin Johns. These collaborations have led to the creation of cutting-edge technologies and have further solidified Kawasuji's reputation as a trailblazer in the industry.

Conclusion:

In conclusion, Takashi Kawasuji's unwavering passion for innovation and his relentless pursuit of excellence have established him as a true pioneer in the world of technology. His groundbreaking inventions and collaborative efforts continue to inspire and shape the future of technological advancements, leaving an indelible mark on the industry.

This text is generated by artificial intelligence and may not be accurate.